ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

Legal Focus on Drug Efficacy: Partner Reed Kathrein Scrutinizing Alleged Misrepresentations of Efzofitimod's Steroid-Tapering Capability

SAN FRANCISCO, Nov. 28, 2025 /PRNewswire/ -- Global plaintiffs' rights law firm Hagens Berman reminds investors of the December 8, 2025, deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit filed against aTyr Pharma, Inc. (NASDAQ: ATYR). The litigation follows a catastrophic 83% single-day stock collapse after the company's flagship drug trial failed to meet its primary endpoint.

The lawsuit alleges that aTyr and its executives provided materially false and misleading information about the efficacy of its drug, Efzofitimod, leading investors to purchase stock at artificially inflated prices.

"In biotech securities cases, the core issue is often whether the company was accurately representing its data and trial design," said Reed Kathrein, the Hagens Berman partner leading the litigation. "The suit alleges that aTyr concealed material adverse facts concerning Efzofitimod's capability to allow a patient to completely taper their steroid usage—a key measure of efficacy—while emphasizing a multi-billion-dollar market. We are scrutinizing whether these prior statements about the drug's prospects crossed the line into securities law violations. The firm urges investors in aTyr who suffered significant losses to submit your losses now."

Legal Analysis: The Clinical Trial Disclosure Gap

Hagens Berman's investigation and the underlying complaint focus on the alleged gap between the company's optimistic public statements and the undisclosed reality of the drug's performance in the Phase 3 EFZO-FIT study.

Next Steps: Contact Hagens Berman Today

Hagens Berman has a proven track record of securing more than $2.9 billion in settlements for investors in this area of law.

The firm is advising investors who purchased ATYR shares during the Class Period (November 7, 2024, through September 12, 2025) and suffered substantial losses due to the undisclosed trial flaws. The Lead Plaintiff Deadline is December 8, 2025.

TO SUBMIT YOUR ATYR STOCK LOSSES NOW, PLEASE USE THE SECURE FORM BELOW:

• Submit your aTyr Pharma (ATYR) Stock Losses
• Contact: Reed Kathrein at 844-916-0895 or email [email protected]

Investors may also read more about the investigation here: The Stakes of Clinical Trials: Why Pharma Companies Must Be Accurate and How it Relates to the aTyr Investigation.  Or visit the case page here: www.hbsslaw.com/investor-fraud/atyr

If you'd like answers to frequently asked questions about the aTyr case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding aTyr should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

SOURCE Hagens Berman Sobol Shapiro LLP